MODEL SPOTLIGHT | MB49: A Bladder Cancer Murine Tumor Model
Bladder cancer is one of the most frequent cancers of the urinary tract, accounting for about 80,000 new cases and 18,000 deaths in the United States in 2018, according to the National Cancer Society. In an effort to meet the need for advances in bladder cancer treatment, the MB49 model has been characterized by our team.
The MB49 murine bladder carcinoma model can be employed as a robust preclinical immuno-oncology model. Our data supports the use of this tool in investigating novel treatment combinations with checkpoint inhibitors or costimulatory molecules. Please contact us to speak with our scientists about how MB49, or one of our other syngeneic models, can be used for your next immuno-oncology study.
Read the full model spotlight to see our data pertaining to anti-tumor activity in the MB49 model following treatment with checkpoint inhibitor or costimulatory antibodies.